Skip to content

A Randomized, Comparative Effectiveness Study of Staged Complete Revascularization with Percutaneous Coronary Intervention to Treat Coronary Artery Disease vs Medical Management Alone in Patients with Symptomatic Aortic Valve Stenosis undergoing Elective Transfemoral Transcatheter Aortic Valve Replacement: The COMPLETE TAVR Study
Principal Investigator: Natalia Berry, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

C4071008: A Low-Interventional Longitudinal Study Of An Electronic Sickle Cell Disease Patient Reported Outcomes In Adult Participants Aged ≥18 Years Of Age
Sponsor: Pfizer
Principal Investigator: Bogdan Dumitriu, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement
Principal Investigator: Natalia Berry, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

AG348-C-020: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
Principal Investigator: Bogdan Dumitriu, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

VX21-147-301: A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Principal Investigator: PI: Tulsi Mehta, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Ferring SCOPE: Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults with Recurrent Clostridioides Difficile Infection
Principal Investigator: PI: David Yoho, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years
Principal Investigator: PI: Michael Horberg, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

No Clinical Trials

KMT013: A Multisite Prospective Study to Assess the Clinical Effectiveness of a Novel Medical Technology as an Extra Reader for Breast Cancer Screening
Principal Investigator: Wilbur Chang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Sponsor: ALCHEMIST
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Sponsor: ALCHEMIST
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Sponsor: ALCHEMIST
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

NRG-GI004: Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Lung-MAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

S1900E: A Phase II Study of Sotorasib (AMG 510) in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

S1900G: A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

NRG-GI005: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

S2302: Pragmatica – Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

NRG-CC005: FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

EA1151: Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Principal Investigator: Ainsley MacLean, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Back To Top